BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26296882)

  • 1. Brain-expressed X-linked 2 Is Pivotal for Hyperactive Mechanistic Target of Rapamycin (mTOR)-mediated Tumorigenesis.
    Hu Z; Wang Y; Huang F; Chen R; Li C; Wang F; Goto J; Kwiatkowski DJ; Wdzieczak-Bakala J; Tu P; Liu J; Zha X; Zhang H
    J Biol Chem; 2015 Oct; 290(42):25756-65. PubMed ID: 26296882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.
    Wang F; Chen X; Li C; Sun Q; Chen Y; Wang Y; Peng H; Liu Z; Chen R; Liu K; Yan H; Ye BH; Kwiatkowski DJ; Zhang H
    Oncogene; 2014 Aug; 33(34):4352-8. PubMed ID: 24077282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.
    Gao Y; Gartenhaus RB; Lapidus RG; Hussain A; Zhang Y; Wang X; Dan HC
    Mol Cancer Res; 2015 Dec; 13(12):1602-14. PubMed ID: 26374334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth.
    Zha X; Hu Z; Ji S; Jin F; Jiang K; Li C; Zhao P; Tu Z; Chen X; Di L; Zhou H; Zhang H
    Cancer Lett; 2015 Apr; 359(1):97-106. PubMed ID: 25578782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis.
    Li C; Chen H; Lan Z; He S; Chen R; Wang F; Liu Z; Li K; Cheng L; Liu Y; Sun K; Wan X; Chen X; Peng H; Li L; Zhang Y; Jing Y; Huang M; Wang Y; Wang Y; Jiang J; Zha X; Chen L; Zhang H
    Cell Death Differ; 2019 Oct; 26(10):2015-2028. PubMed ID: 30760873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
    Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
    Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis.
    Zha X; Wang F; Wang Y; He S; Jing Y; Wu X; Zhang H
    Cancer Res; 2011 Jan; 71(1):13-8. PubMed ID: 21199794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade.
    Ma J; Meng Y; Kwiatkowski DJ; Chen X; Peng H; Sun Q; Zha X; Wang F; Wang Y; Jing Y; Zhang S; Chen R; Wang L; Wu E; Cai G; Malinowska-Kolodziej I; Liao Q; Liu Y; Zhao Y; Sun Q; Xu K; Dai J; Han J; Wu L; Zhao RC; Shen H; Zhang H
    J Clin Invest; 2010 Jan; 120(1):103-14. PubMed ID: 20038814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant mTOR/autophagy/Nurr1 signaling is critical for TSC-associated tumor development.
    Wang Y; Li C; Zhang Y; Zha X; Zhang H; Hu Z; Wu C
    Biochem Cell Biol; 2021 Oct; 99(5):570-577. PubMed ID: 34463540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
    Li H; Jin F; Jiang K; Ji S; Wang L; Ni Z; Chen X; Hu Z; Zhang H; Liu Y; Qin Y; Zha X
    Oncotarget; 2016 May; 7(19):28435-47. PubMed ID: 27078846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
    Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
    J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MTOR inhibition attenuates DNA damage and apoptosis through autophagy-mediated suppression of CREB1.
    Wang Y; Hu Z; Liu Z; Chen R; Peng H; Guo J; Chen X; Zhang H
    Autophagy; 2013 Dec; 9(12):2069-86. PubMed ID: 24189100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival.
    Ghosh S; Tergaonkar V; Rothlin CV; Correa RG; Bottero V; Bist P; Verma IM; Hunter T
    Cancer Cell; 2006 Sep; 10(3):215-26. PubMed ID: 16959613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
    Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
    Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
    Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
    Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.
    Sun Q; Chen X; Ma J; Peng H; Wang F; Zha X; Wang Y; Jing Y; Yang H; Chen R; Chang L; Zhang Y; Goto J; Onda H; Chen T; Wang MR; Lu Y; You H; Kwiatkowski D; Zhang H
    Proc Natl Acad Sci U S A; 2011 Mar; 108(10):4129-34. PubMed ID: 21325052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
    J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.